Get started
Author

Takeo Kurihashi

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
2021 · Masato Yoneda, Yasushi Honda, et al. · BMJ Open Diabetes Research & Care · 99
Periodontal Treatment and Usual Care for Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized Controlled Trial
2022 · Yohei Kamata, Takaomi Kessoku, et al. · Clinical and Translational Gastroenterology · 36
A cross-sectional study assessing the relationship between non-alcoholic fatty liver disease and periodontal disease
2022 · Satsuki Sato, Yohei Kamata, et al. · Scientific Reports · 27
PDF
Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial
2020 · Yohei Kamata, Takaomi Kessoku, et al. · Trials · 22
PDF
Natural History of Chronic Intestinal Pseudo-obstruction and Need for Palliative Care
2023 · Kosuke Tanaka, Hidenori Ohkubo, et al. · Journal of Neurogastroenterology and Motility · 14
PDF
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
2019 · Anna Ozaki, Masato Yoneda, et al. · Contemporary Clinical Trials Communications · 12
PDF
Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol
2024 · Michihiro Iwaki, Takashi Kobayashi, et al. · BMJ Open · 10
PDF
The Prevalence and Characteristics of Symptomatic Uncomplicated Diverticular Disease Among Asian Patients With Unexplained Abdominal Symptoms
2023 · Tsumugi Jono, Yuki Kasai, et al. · Journal of Neurogastroenterology and Motility · 10
PDF
Comparison of the Effectiveness of Magnesium Oxide and Elobixibat on Improving Rectal Sensitivity and Colonic Transit Time in Patients With Chronic Constipation: An Observational Study
2025 · Takaomi Kessoku, Yo Ishihara, et al. · Neurogastroenterology & Motility · 5
Efficacy and safety of linaclotide in treatment‐resistant chronic constipation: A multicenter, open‐label study
2024 · Tsutomu Yoshihara, Takaomi Kessoku, et al. · Neurogastroenterology & Motility · 4
PDF
Exploratory, multicenter, open-label study to evaluate the effects of linaclotide in patients with chronic constipation with an insufficient response to magnesium oxide: A study protocol
2022 · Tsutomu Yoshihara, Takaomi Kessoku, et al. · Contemporary Clinical Trials Communications · 3
PDF
Dependence-related screening positivity among regular stimulant-laxative users with chronic constipation: a multicenter prospective observational study
2026 · Yo Ishihara, Eikichi Ihara, et al. · Journal of Gastroenterology · 2
PDF
Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation
2022 · Kosuke Tanaka, Takaomi Kessoku, et al. · BMJ Open · 2
PDF
Relationship between non-alcoholic fatty liver disease and periodontal disease: a review and study protocol on the effect of periodontal treatment on non-alcoholic fatty liver disease
2016 · Chieko Kudo, Takaomi Kessoku, et al. · Journal of Translational Science · 2
PDF
Patients with symptomatic uncomplicated diverticular disease have high fecal bile acid concentrations
2025 · Tsumugi Jono, Yuki Kasai, et al. · Frontiers in Medicine · 1
PDF
Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation
2022 · Atsushi Yamamoto, Takaomi Kessoku, et al. · Contemporary Clinical Trials Communications · 1
PDF
Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trial
2026 · Michihiro Iwaki, Hiroshi Tobita, et al. · EClinicalMedicine
Significant alteration of gut microbiota in patients with symptomatic uncomplicated diverticular disease
2026 · Fumiaki Ishibashi, Tsumugi Jono, et al. · Scientific Reports
PDF
Multicentre, double-blind, randomised, placebo-controlled study on the prophylactic use of naldemedine for opioid-induced nausea and vomiting in patients with cancer (POSEIDON study): a protocol paper
2026 · Yo Ishihara, Mayumi Ohira, et al. · BMJ Open
FRI-159 Dose-dependent efficacy and renal safety of pemafibrate in patients with MASLD: a multicenter randomized controlled trial
2026 · Michihiro Iwaki, Takashi Kobayashi, et al. · Journal of Hepatology
Impact of Chronic Constipation and Subtypes on Serum Trimethylamine-N-Oxide Levels and Their Reduction With Treatment: Multicenter Observational Study
2026 · Yo Ishihara, Eikichi Ihara, et al. · Clinical and Translational Gastroenterology
Therapeutic Impact on Quality of Life in Adult Patients With Chronic Intestinal Pseudo-obstruction: A Multicenter, Cohort Study
2026 · Kota Takahashi, Takaomi Kessoku, et al. · Journal of Neurogastroenterology and Motility
PDF
Bifidobacterium bifidum G9-1 and Quality of Life in Chronic Constipation: A Multicenter, Double-Blind, Randomized Controlled Trial
2026 · Noboru Misawa, Takaomi Kessoku, et al. · Digestion
PDF
Dose-Dependent Efficacy and Renal Safety of Pemafibrate versus Fenofibrate in Patients with MASLD and Hypertriglyceridemia: A Multicenter Randomized Controlled Trial
2026 · Michihiro Iwaki, Hiroshi Tobita, et al. · SSRN Electronic Journal
Effect of Bifidobacterium bifidum G9-1 on fecal short chain fatty acids in patients with chronic constipation: a multicenter, observational study
2022 · Tomoki Ogata, Takaomi Kessoku, et al. · Research Square
PDF
Works count: 26
Citation count: 250
H-index: 8
I10-index: 8
Year
Topic
Type